Revance Logo
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
ABOUTLEADERSHIPBOARDPARTNERSHIPS
SUSTAINABILITYMEDICAL EDUCATIONAL GRANTSINVESTIGATOR SPONSORED TRIALS
Company
INVESTOR RELATIONSPRESS RELEASESEVENTS + PRESENTATIONSFINANCIALS & FILINGSCORPORATE GOVERNANCE
STOCK INFORMATIONANALYST COVERAGEINVESTOR FAQSCONTACT US
Investors
OPPORTUNITIESCULTUREBENEFITS
Careers
COMPANYPRODUCTS AND PIPELINEINVESTORSCAREERSIN THE NEWSCONTACT US
Facebook logoInstagram logoTwitter logoLinkedIn logo
1222 Demonbreun St
20th Floor
Nashville, TN 37203
+1 (510) 742-3400
LoginContact Revance
Back
January 9, 2023
Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results
January 6, 2023
Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
November 22, 2022
Revance to Participate in the 34th Annual Piper Sandler Healthcare Conference
November 9, 2022
Revance to Participate in the Stifel 2022 Healthcare Conference
November 8, 2022
Revance Reports Third Quarter 2022 Financial Results, Provides Corporate Update
November 4, 2022
Revance Announces Two Publications in The Aesthetic Surgery Journal That Advance Glabellar Line Injection Technique and Assessment
November 1, 2022
Revance to Release Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
October 20, 2022
Revance Submits Supplemental Biologics License Application (sBLA) for DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
October 17, 2022
Revance Appoints David A. Hollander, M.D., M.B.A. as Chief Medical Officer
October 10, 2022
Revance to Present Clinical Data on the Efficacy and Safety Profile of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting
Displaying 1 - 10 of 298